Mouse anti-Human Complement C3a Monoclonal Antibody | anti-C3 antibody

Complement C3a, Human

Cat. Num. AAA631950

• Gene Names: C3; ASP; C3a; C3b; AHUS5; ARMD9; CPAMD1
• Reactivity: Human
• Applications: ELISA, Western Blot
• Purity: Affinity Purified; Purified by Protein G affinity chromatography.
• Synonyms: Complement C3a; Monoclonal Antibody; Human; Anti -Complement C3a; anti-C3 antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG2b
• Clone Number: 7H121
• Specificity: Recognizes human Complement C3a. Shows no crossreactivity with recombinant human C5a or recombinant human C3d.
• Purity/Purification: Affinity Purified; Purified by Protein G affinity chromatography.
• Form/Format: Supplied as a lyophilized powder from PBS, 5% trehalose. Reconstitute with 200ul sterile PBS.

• Applicable Applications for anti-C3 antibody: ELISA (EL/EIA), Western Blot (WB)
• Application Notes: Dilution: Western Blot: 1-2ug/ml. The detection limit is ~25ng/lane under non-reducing conditions. Reducing conditions are not recommended. Chemiluminescent detection will increase sensitivity by 5 to 50 fold.; Direct ELISA: 0.5-1.0ug/ml. The detection limit is ~10ng/well.; Optimal dilution determined by the researcher.
• Immunogen: E. coli-derived recombinant human C3a.
• Preparation and Storage: Lyophilized powder may be stored at -20 degree C. Stable for 12 months at -20 degree C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Reconstituted product is stable for 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Related Product Information for anti-C3 antibody

C3a is a 77 amino acid (aa) peptide comprising aa 672-748 of the C3 precursor protein. It is generated as a proteolytic byproduct of complement activation. C3a is an anaphylatoxin that is vasoactive and mediates inflammatory responses. It binds G-protein coupled C3a receptors in airways during asthmatic allergen challenges, triggering robust mast cell degranulation. Human C3a shows 69% aa identity with mouse, rat and guinea pig C3a.

Product Categories/Family for anti-C3 antibody

Antibodies; Abs to Complement

NCBI and Uniprot Product Information

• NCBI GI #: 115298678
• NCBI GeneID: 718
• NCBI Accession #: NP_000055.2
• NCBI GenBank Nucleotide #: NM_000064.2
• UniProt Accession #: P01024; A7E236
• Molecular Weight: 187,148 Da
• NCBI Official Full Name: complement C3
• NCBI Official Synonym Full Names: complement component 3
• NCBI Official Symbol: C3
• NCBI Official Synonym Symbols: ASP; C3a; C3b; AHUS5; ARMD9; CPAMD1
• NCBI Protein Information: complement C3; prepro-C3; C3a anaphylatoxin; complement component C3; complement component C3a; complement component C3b; acylation-stimulating protein cleavage product; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1
• UniProt Protein Name: Complement C3
• Protein Family: Complement C3
• UniProt Gene Name: C3
• UniProt Synonym Gene Names: CPAMD1; ASP
• UniProt Entry Name: CO3_HUMAN

NCBI Description

Complement component C3 plays a central role in the activation of complement system. Its activation is required for both classical and alternative complement activation pathways. People with C3 deficiency are susceptible to bacterial infection. [provided by RefSeq, Feb 2009]

Uniprot Description

C3: C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. Defects in C3 are the cause of complement component 3 deficiency (C3D). A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis. Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9). ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin- containing structure known as Bruch membrane. Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5). An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. Increased levels of C3 and its cleavage product ASP, are associated with obesity, diabetes and coronary heart disease. Short-term endurance training reduces baseline ASP levels and subsequently fat storage.

Protein type: Inhibitor; Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 19p13.3-p13.2

Cellular Component: extracellular space; extracellular region; plasma membrane

Molecular Function: protein binding; endopeptidase inhibitor activity; C5L2 anaphylatoxin chemotactic receptor binding; receptor binding

Biological Process: regulation of immune response; complement activation, alternative pathway; fatty acid metabolic process; signal transduction; complement activation; G-protein coupled receptor protein signaling pathway; positive regulation of angiogenesis; positive regulation of activation of membrane attack complex; positive regulation of type IIa hypersensitivity; positive regulation of G-protein coupled receptor protein signaling pathway; regulation of complement activation; innate immune response; immune response; positive regulation of protein amino acid phosphorylation; inflammatory response; complement activation, classical pathway

Disease: Complement Component 3 Deficiency, Autosomal Recessive; Hemolytic Uremic Syndrome, Atypical, Susceptibility To, 5; Macular Degeneration, Age-related, 9